{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:45:28Z","timestamp":1790952328954,"version":"4.1.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research Bonn Office","doi-asserted-by":"publisher","award":["03INT703AB"],"award-info":[{"award-number":["03INT703AB"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research Bonn Office","doi-asserted-by":"publisher","award":["16GW0262K"],"award-info":[{"award-number":["16GW0262K"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["453989101 B03\/PS1"],"award-info":[{"award-number":["453989101 B03\/PS1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["CRC1525"],"award-info":[{"award-number":["CRC1525"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014690","name":"Ministerium f\u00fcr Kultur und Wissenschaft des Landes Nordrhein-Westfalen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014690","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.molmed.2025.08.001","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T15:12:34Z","timestamp":1757085154000},"page":"231-255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Targeting pathological ERK1\/2 signaling in cancer and beyond"],"prefix":"10.1016","volume":"32","author":[{"given":"Constanze","family":"Schanbacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Elisabeth","family":"Goebeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Gerull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5747-2207","authenticated-orcid":false,"given":"Kristina","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2025.08.001_bb0005","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1016\/j.devcel.2021.11.022","article-title":"ERK1\/2 inhibition promotes robust myotube growth via CaMKII activation resulting in myoblast-to-myotube fusion","volume":"56","author":"Eigler","year":"2021","journal-title":"Dev. Cell"},{"key":"10.1016\/j.molmed.2025.08.001_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceb.2025.102526","article-title":"ERK1\/2\u2013MAPK signaling: metabolic, organellar, and cytoskeletal interactions","volume":"95","author":"Martin-Vega","year":"2025","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceca.2022.102540","article-title":"Injury-induced Erk1\/2 signaling tissue-specifically interacts with Ca2+ activity and is necessary for regeneration of spinal cord and skeletal muscle","volume":"102","author":"Levin","year":"2022","journal-title":"Cell Calcium"},{"key":"10.1016\/j.molmed.2025.08.001_bb0020","doi-asserted-by":"crossref","first-page":"7440","DOI":"10.1073\/pnas.1221999110","article-title":"Interference with ERK(Thr188) phosphorylation impairs pathological but not physiological cardiac hypertrophy","volume":"110","author":"Ruppert","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2025.08.001_bb0025","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.3390\/ijms20092164","article-title":"ERK: a key player in the pathophysiology of cardiac hypertrophy","volume":"20","author":"Gallo","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2025.08.001_bb0030","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3390\/cancers14040867","article-title":"Harnessing RKIP to combat heart disease and cancer","volume":"14","author":"Lorenz","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molmed.2025.08.001_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109541","article-title":"The road to ERK activation: do neurons take alternate routes?","volume":"68","author":"Miningou","year":"2020","journal-title":"Cell. Signal."},{"key":"10.1016\/j.molmed.2025.08.001_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2024.1388409","article-title":"Developmental effect of RASopathy mutations on neuronal network activity on a chip","volume":"18","author":"Weiss","year":"2024","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.molmed.2025.08.001_bb0045","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1016\/j.biocel.2009.08.002","article-title":"Cardiac hypertrophy: targeting Raf\/MEK\/ERK1\/2-signaling","volume":"41","author":"Lorenz","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0050","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrc4000","article-title":"MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road","volume":"15","author":"Caunt","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.molmed.2025.08.001_bb0055","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049107","article-title":"The RASopathies: from pathogenetics to therapeutics","volume":"15","author":"Hebron","year":"2022","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.molmed.2025.08.001_bb0060","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1749-6632.2009.05088.x","article-title":"Extracellular signal-regulated kinase 1\/2 (ERK1\/2) signaling in cardiac hypertrophy","volume":"1188","author":"Kehat","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.molmed.2025.08.001_bb0065","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1042\/BST20220271","article-title":"ERK1\/2 in immune signalling","volume":"50","author":"Lucas","year":"2022","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.molmed.2025.08.001_bb0070","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3390\/biom13101555","article-title":"Navigating the ERK1\/2 MAPK cascade","volume":"13","author":"Martin-Vega","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.molmed.2025.08.001_bb0075","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.3390\/cells10102509","article-title":"ERK: a double-edged sword in cancer. ERK-dependent apoptosis as a potential therapeutic strategy for cancer","volume":"10","author":"Sugiura","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.molmed.2025.08.001_bb0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.02.007","article-title":"ERK1\/2 inhibitors: new weapons to inhibit the RAS-regulated RAF\u2013MEK1\/2\u2013ERK1\/2 pathway","volume":"187","author":"Kidger","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2025.08.001_bb0085","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1007\/s00018-016-2297-8","article-title":"Negative feedback regulation of the ERK1\/2 MAPK pathway","volume":"73","author":"Lake","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.molmed.2025.08.001_bb0090","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145035","article-title":"Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer","volume":"131","author":"Liu","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2025.08.001_bb0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/bs.apha.2024.04.001","article-title":"Progress in the development of ERK1\/2 inhibitors for treating cancer and other diseases","volume":"100","author":"Grogan","year":"2024","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.molmed.2025.08.001_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.142206","article-title":"A comprehensive review of RAF kinase: advances in inhibition strategies for drug development","volume":"1337","author":"Kahvecioglu","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.molmed.2025.08.001_bb0110","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/1878-0261.13605","article-title":"Novel RAF-directed approaches to overcome current clinical limits and block the RAS\/RAF node","volume":"18","author":"Scardaci","year":"2024","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0115","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.tips.2019.09.005","article-title":"Comprehensive analysis of ERK1\/2 substrates for potential combination immunotherapies","volume":"40","author":"Yang","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.molmed.2025.08.001_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113386","article-title":"Research progress of MEK1\/2 inhibitors and degraders in the treatment of cancer","volume":"218","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.molmed.2025.08.001_bb0125","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-12-0742","article-title":"First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK\/RAF inhibitor in patients with solid tumors","volume":"18","author":"Martinez-Garcia","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2025.08.001_bb0130","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107207118","article-title":"Allosteric MEK inhibitors act on BRAF\/MEK complexes to block MEK activation","volume":"118","author":"Gonzalez-Del Pino","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2025.08.001_bb0135","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1042\/BCJ20220598","article-title":"ERK1\/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1","volume":"480","author":"Balmanno","year":"2023","journal-title":"Biochem. J."},{"key":"10.1016\/j.molmed.2025.08.001_bb0140","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature12441","article-title":"Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers","volume":"501","author":"Hatzivassiliou","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2025.08.001_bb0145","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ccr.2014.03.011","article-title":"Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors","volume":"25","author":"Lito","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2025.08.001_bb0150","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2025.08.001_bb0155","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/2159-8290.CD-14-1518","article-title":"Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations","volume":"5","author":"Ahronian","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2025.08.001_bb0160","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/onc.2012.160","article-title":"Mechanisms of acquired resistance to ERK1\/2 pathway inhibitors","volume":"32","author":"Little","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.molmed.2025.08.001_bb0165","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1039\/D3MD00145H","article-title":"MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives","volume":"14","author":"Ram","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.molmed.2025.08.001_bb0170","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2025.08.001_bb0175","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/acs.jmedchem.9b00810","article-title":"Design, synthesis, and biological evaluation of MEK PROTACs","volume":"63","author":"Vollmer","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2025.08.001_bb0180","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.tips.2022.04.006","article-title":"Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules","volume":"43","author":"Goebel","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.molmed.2025.08.001_bb0185","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic \u2013 a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0190","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.molmed.2025.08.001_bb0195","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1158\/1535-7163.MCT-19-0505","article-title":"Dual-mechanism ERK1\/2 inhibitors exploit a distinct binding mode to block phosphorylation and nuclear accumulation of ERK1\/2","volume":"19","author":"Kidger","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.molmed.2025.08.001_bb0200","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.91507.3","article-title":"Conformation selection by ATP-competitive inhibitors and allosteric communication in ERK2","volume":"12","author":"Anderson","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.molmed.2025.08.001_bb0205","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1128\/MCB.00800-07","article-title":"Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels","volume":"28","author":"Lefloch","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216290","article-title":"Design, synthesis, and antitumor activity evaluation of proteolysis-targeting chimeras as degraders of extracellular signal-regulated kinases 1\/2","volume":"24","author":"Pan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2025.08.001_bb0215","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1158\/1541-7786.MCR-17-0554","article-title":"Efficacy of a covalent ERK1\/2 inhibitor, CC-90003, in KRAS-mutant cancer models reveals novel mechanisms of response and resistance","volume":"17","author":"Aronchik","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.molmed.2025.08.001_bb0220","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/toxsci\/kfab033","article-title":"Investigation into the role of ERK in tyrosine kinase inhibitor-induced neuropathy","volume":"181","author":"Belair","year":"2021","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.molmed.2025.08.001_bb0225","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1038\/s41467-019-12996-8","article-title":"Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo","volume":"10","author":"Kaoud","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.08.001_bb0230","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/BJ20131571","article-title":"Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf","volume":"467","author":"Samadani","year":"2015","journal-title":"Biochem. J."},{"key":"10.1016\/j.molmed.2025.08.001_bb0235","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/mc.23047","article-title":"Targeting ERK beyond the boundaries of the kinase active site in melanoma","volume":"58","author":"Sammons","year":"2019","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.molmed.2025.08.001_bb0240","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1021\/acschembio.9b00093","article-title":"A novel class of common docking domain inhibitors that prevent ERK2 activation and substrate phosphorylation","volume":"14","author":"Sammons","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0245","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1165\/rcmb.2022-0110OC","article-title":"Targeted inhibition of select extracellular signal-regulated kinases 1 and 2 functions mitigates pathological features of asthma in mice","volume":"68","author":"Shah","year":"2023","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0250","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ccell.2015.07.001","article-title":"Small molecule inhibition of ERK dimerization prevents tumorigenesis by RAS\u2013ERK pathway oncogenes","volume":"28","author":"Herrero","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2025.08.001_bb0255","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41467-020-15505-4","article-title":"Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1\/2 signaling without cardiotoxic side-effects","volume":"11","author":"Tomasovic","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.08.001_bb0260","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/1878-0261.13732","article-title":"ERK1\/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility","volume":"19","author":"de la Fuente-Vivas","year":"2025","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0265","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nm.1893","article-title":"A new type of ERK1\/2 autophosphorylation causes cardiac hypertrophy","volume":"15","author":"Lorenz","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2025.08.001_bb0270","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s11030-020-10088-0","article-title":"Structure-activity relationship study of DEL-22379: ERK dimerization inhibitors with increased safety","volume":"25","author":"Yang","year":"2021","journal-title":"Mol. Divers."},{"key":"10.1016\/j.molmed.2025.08.001_bb0275","doi-asserted-by":"crossref","first-page":"13130","DOI":"10.1039\/D4SC01088D","article-title":"The prospect of substrate-based kinase inhibitors to improve target selectivity and overcome drug resistance","volume":"15","author":"Biswas","year":"2024","journal-title":"Chem. Sci."},{"key":"10.1016\/j.molmed.2025.08.001_bb0280","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.molmed.2025.08.001_bb0285","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-024-01631-9","article-title":"RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms","volume":"17","author":"Yang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0290","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/1947601911407323","article-title":"Raf family kinases: old dogs have learned new tricks","volume":"2","author":"Matallanas","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.molmed.2025.08.001_bb0295","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.apsb.2018.01.008","article-title":"Targeting ERK, an Achilles\u2019 heel of the MAPK pathway, in cancer therapy","volume":"8","author":"Liu","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.molmed.2025.08.001_bb0300","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1634\/theoncologist.2017-0642","article-title":"FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations","volume":"23","author":"Odogwu","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.molmed.2025.08.001_bb0305","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.08.001_bb0310","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1158\/1535-7163.MCT-19-0183","article-title":"ERK inhibitor LY3214996 targets ERK pathway-driven cancers: a therapeutic approach toward precision medicine","volume":"19","author":"Bhagwat","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.molmed.2025.08.001_bb0315","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/1061186X.2019.1648477","article-title":"Development of ERK1\/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations","volume":"28","author":"Miao","year":"2020","journal-title":"J. Drug Target."},{"key":"10.1016\/j.molmed.2025.08.001_bb0320","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1093\/oncolo\/oyac237","article-title":"Phase Ib study of ulixertinib plus gemcitabine and nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma","volume":"28","author":"Grierson","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.molmed.2025.08.001_bb0325","article-title":"ASN007 is a selective ERK1\/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors","volume":"2","author":"Portelinha","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.molmed.2025.08.001_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104250","article-title":"Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236","volume":"30","author":"Filis","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.molmed.2025.08.001_bb0335","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011551","article-title":"Sensitivity to immune checkpoint inhibitors in BRAF\/MEK inhibitor refractory melanoma","volume":"13","author":"Patel","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molmed.2025.08.001_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102650","article-title":"A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NCT03991819)","volume":"9","author":"Theriau","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.molmed.2025.08.001_bb0345","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/s41467-020-15979-2","article-title":"Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy","volume":"11","author":"Baumann","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.08.001_bb0350","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40258-025-00949-w","article-title":"The cost effectiveness of genomic medicine in cancer control: a systematic literature review","volume":"23","author":"Bourke","year":"2025","journal-title":"Appl. Health Econ. Health Policy"},{"key":"10.1016\/j.molmed.2025.08.001_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1466946","article-title":"Case report: MEK inhibitor as treatment for multi-lineage mosaic KRAS G12D-associated epidermal nevus syndrome in a pediatric patient","volume":"15","author":"Dionysiou","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0360","first-page":"731","article-title":"Exploring new drug repurposing opportunities for MEK inhibitors in RASopathies: a comprehensive review of safety, efficacy, and future perspectives of trametinib and selumetinib","volume":"14","author":"Gazzin","year":"2024","journal-title":"Life (Basel)"},{"key":"10.1016\/j.molmed.2025.08.001_bb0365","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00431-023-05263-y","article-title":"Novel therapeutic perspectives in Noonan syndrome and RASopathies","volume":"183","author":"Saint-Laurent","year":"2024","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.molmed.2025.08.001_bb0370","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/genes13010006","article-title":"MEK inhibition in a newborn with RAF1-associated Noonan syndrome ameliorates hypertrophic cardiomyopathy but is insufficient to revert pulmonary vascular disease","volume":"13","author":"Mussa","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.molmed.2025.08.001_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.1001105","article-title":"Case report: progressive central conducting lymphatic abnormalities in the RASopathies. Two case reports, including successful treatment by MEK inhibition","volume":"13","author":"Gordon","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.molmed.2025.08.001_bb0380","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jacbts.2024.10.002","article-title":"Impact of MEK inhibition on childhood RASopathy-associated hypertrophic cardiomyopathy","volume":"10","author":"Wolf","year":"2025","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.molmed.2025.08.001_bb0385","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1172\/JCI44929","article-title":"MEK\u2013ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation","volume":"121","author":"Wu","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2025.08.001_bb0390","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s42003-023-05013-8","article-title":"Molecular and cellular evidence for the impact of a hypertrophic cardiomyopathy-associated RAF1 variant on the structure and function of contractile machinery in bioartificial cardiac tissues","volume":"6","author":"Nakhaei-Rad","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0395","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-20-5032","article-title":"FDA approval summary: selumetinib for plexiform neurofibroma","volume":"27","author":"Casey","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2025.08.001_bb0400","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.24.01034","article-title":"ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma","volume":"43","author":"Moertel","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0405","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.20.02220","article-title":"NF106: a Neurofibromatosis Clinical Trials Consortium Phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas","volume":"39","author":"Weiss","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0410","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-056336","article-title":"Selumetinib for refractory pulmonary and gastrointestinal bleeding in Noonan syndrome","volume":"150","author":"Chakraborty","year":"2022","journal-title":"Pediatrics"},{"key":"10.1016\/j.molmed.2025.08.001_bb0415","first-page":"1342","article-title":"Refractory chylothorax and ventricular hypertrophy treated with trametinib in a patient with Noonan syndrome: 18-month follow-up","volume":"11","author":"Pascarella","year":"2024","journal-title":"Children (Basel)"},{"key":"10.1016\/j.molmed.2025.08.001_bb0420","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.121.003327","article-title":"Molecular management of multifocal atrial tachycardia in Noonan\u2019s syndrome with MEK1\/2 inhibitor trametinib","volume":"14","author":"Meisner","year":"2021","journal-title":"Circ. Genom. Precis. Med."},{"key":"10.1016\/j.molmed.2025.08.001_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2022.104630","article-title":"Succesful MEK-inhibition of severe hypertrophic cardiomyopathy in RIT1-related Noonan syndrome","volume":"65","author":"Leegaard","year":"2022","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.molmed.2025.08.001_bb0430","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pediatrneurol.2023.08.019","article-title":"Treatment of refractory epilepsy with MEK inhibitor in patients with RASopathy","volume":"148","author":"D'Onofrio","year":"2023","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0435","first-page":"789","article-title":"MEK inhibition for RASopathy-associated hypertrophic cardiomyopathy: clinical application of a basic concept","volume":"40","author":"Chaput","year":"2024","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0440","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.9164","article-title":"Trametinib restores the central conducting lymphatic flow in a premature infant with Noonan syndrome","volume":"12","author":"Leenders","year":"2024","journal-title":"Clin. Case Rep."},{"key":"10.1016\/j.molmed.2025.08.001_bb0445","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.jacc.2019.01.066","article-title":"Hypertrophic cardiomyopathy in Noonan syndrome treated by MEK-inhibition","volume":"73","author":"Andelfinger","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0450","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jpeds.2022.05.030","article-title":"Trametinib for refractory chylous effusions and systemic complications in children with Noonan syndrome","volume":"248","author":"Nakano","year":"2022","journal-title":"J. Pediatr."},{"key":"10.1016\/j.molmed.2025.08.001_bb0455","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1038\/s41467-022-31690-w","article-title":"Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancer","volume":"13","author":"Kubota","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.08.001_bb0460","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1404253","article-title":"MEK inhibitors: a promising targeted therapy for cardiovascular disease","volume":"11","author":"Mohammed","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.molmed.2025.08.001_bb0465","first-page":"1034","article-title":"Inhibition of MEK\/ERK\/STAT3 signaling in oleuropein treatment inhibits myocardial ischemia\/reperfusion","volume":"42","author":"Jin","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.molmed.2025.08.001_bb0470","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.3389\/fphys.2019.01038","article-title":"Role of the extracellular signal-regulated kinase 1\/2 signaling pathway in ischemia-reperfusion injury","volume":"10","author":"Kong","year":"2019","journal-title":"Front. Physiol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0475","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jaccao.2022.07.009","article-title":"Cellular and molecular mechanisms of MEK1 inhibitor-induced cardiotoxicity","volume":"4","author":"Beck","year":"2022","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0480","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41586-024-07501-1","article-title":"A disease-associated gene desert directs macrophage inflammation through ETS2","volume":"630","author":"Stankey","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2025.08.001_bb0485","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nri3495","article-title":"Mitogen-activated protein kinases in innate immunity","volume":"13","author":"Arthur","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0490","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/jnr.24829","article-title":"Extracellular signal-regulated kinase regulates microglial immune responses in Alzheimer's disease","volume":"99","author":"Chen","year":"2021","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.molmed.2025.08.001_bb0495","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1038\/s41380-022-01713-5","article-title":"MEK1\/2 inhibition rescues neurodegeneration by TFEB-mediated activation of autophagic lysosomal function in a model of Alzheimer's disease","volume":"27","author":"Chun","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.molmed.2025.08.001_bb0500","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202215984","article-title":"Nuclear ERK1\/2 signaling potentiation enhances neuroprotection and cognition via Importinalpha1\/KPNA2","volume":"15","author":"Indrigo","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.molmed.2025.08.001_bb0505","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s12012-017-9425-z","article-title":"Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism","volume":"17","author":"Banks","year":"2017","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0510","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaccao.2023.04.004","article-title":"Cardiotoxicity of BRAF\/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores","volume":"5","author":"Glen","year":"2023","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0515","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/0284186X.2021.1992010","article-title":"Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting","volume":"61","author":"Pedersen","year":"2022","journal-title":"Acta Oncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0520","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2018.06.017","article-title":"Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors","volume":"192","author":"Bronte","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2025.08.001_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102282","article-title":"Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors","volume":"100","author":"Arangalage","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.molmed.2025.08.001_bb0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.01.096","article-title":"Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Glen","year":"2022","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0535","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1002\/cam4.3938","article-title":"Cardiovascular adverse events associated with BRAF versus BRAF\/MEK inhibitor: cross-sectional and longitudinal analysis using two large national registries","volume":"10","author":"Guha","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.molmed.2025.08.001_bb0540","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jaccao.2023.09.006","article-title":"Cardiotoxicity of BRAF\/MEK inhibitors according to HFA\/ICOS cardiotoxicity risk category","volume":"5","author":"Courand","year":"2023","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0545","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0550","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.molmed.2025.08.001_bb0555","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/ncb1994","article-title":"Cell fate decisions are specified by the dynamic ERK interactome","volume":"11","author":"von Kriegsheim","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0560","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00424-014-1462-x","article-title":"Heart failure-specific changes in protein kinase signalling","volume":"466","author":"Lorenz","year":"2014","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.molmed.2025.08.001_bb0565","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/cvr\/cvs249","article-title":"\u03b2-Adrenergic receptor stimulation causes cardiac hypertrophy via a G\u03b2\u03b3\/Erk-dependent pathway","volume":"96","author":"Vidal","year":"2012","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.molmed.2025.08.001_bb0570","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCRESAHA.110.231514","article-title":"Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth","volume":"108","author":"Kehat","year":"2011","journal-title":"Circ. Res."},{"key":"10.1016\/j.molmed.2025.08.001_bb0575","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3390\/cells12131780","article-title":"The microenvironment of the pathogenesis of cardiac hypertrophy","volume":"12","author":"Bazgir","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.molmed.2025.08.001_bb0580","doi-asserted-by":"crossref","DOI":"10.1172\/JCI152308","article-title":"Cardiac pericyte reprogramming by MEK inhibition promotes arteriologenesis and angiogenesis of the ischemic heart","volume":"132","author":"Avolio","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2025.08.001_bb0585","series-title":"GeneReviews","article-title":"Noonan syndrome","author":"Roberts","year":"2025"},{"key":"10.1016\/j.molmed.2025.08.001_bb0590","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-0167","article-title":"Severe lymphatic disorder resolved with MEK inhibition in a patient with Noonan syndrome and SOS1 mutation","volume":"146","author":"Dori","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.molmed.2025.08.001_bb0595","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3390\/genes13091503","article-title":"Severe lymphatic disorder and multifocal atrial tachycardia treated with trametinib in a patient with Noonan syndrome and SOS1 mutation","volume":"13","author":"Lioncino","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.molmed.2025.08.001_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114448","article-title":"Mutation-induced LZTR1 polymerization provokes cardiac pathology in recessive Noonan syndrome","volume":"43","author":"Busley","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2025.08.001_bb0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/GIM.0b013e3181bf15e3","article-title":"Clinical and genetic aspects of neurofibromatosis 1","volume":"12","author":"Jett","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.molmed.2025.08.001_bb0610","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","article-title":"Sotorasib for previously treated colorectal cancers with KRAS(G12C) mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial","volume":"23","author":"Fakih","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0615","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-human phase I\/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS(G12C) solid tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0620","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.08.001_bb0625","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.jtho.2023.08.011","article-title":"Current and future treatment options in the management of stage III NSCLC","volume":"18","author":"Li","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0630","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-2600(24)00110-3","article-title":"Garsorasib in patients with KRAS(G12C)-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial","volume":"12","author":"Li","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.molmed.2025.08.001_bb0635","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0640","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","article-title":"Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma","volume":"31","author":"Ascierto","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0645","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0650","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0655","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0660","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s41591-019-0479-2","article-title":"ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor","volume":"25","author":"Li","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2025.08.001_bb0665","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41591-024-03361-4","article-title":"Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial","volume":"31","author":"Gross","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2025.08.001_bb0670","article-title":"Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: an open-label, phase I study","volume":"5","author":"Suenobu","year":"2023","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.molmed.2025.08.001_bb0675","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","article-title":"Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas","volume":"25","author":"Gross","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.molmed.2025.08.001_bb0680","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1007\/s00381-020-04731-2","article-title":"Current status of MEK inhibitors in the treatment of plexiform neurofibromas","volume":"36","author":"Gross","year":"2020","journal-title":"Childs Nerv. Syst."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425001893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425001893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T07:36:14Z","timestamp":1773646574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491425001893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":136,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1471491425001893"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2025.08.001","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting pathological ERK1\/2 signaling in cancer and beyond","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2025.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}